Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CVKD

Cadrenal Therapeutics Inc

May 09 • 04:00PM ET

0.4854

Dollar change -0.0053
Percentage change -1.08	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	46.72%	Shs Outstand	13.02M	Perf Week	4.39%
Market Cap	7.77M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	8.53M	Perf Month	9.74%
Income	-4.85M	PEG	-	EPS next Q	-0.07	Inst Own	3.62%	Short Float	0.80%	Perf Quarter	-46.66%
Sales	0.00M	P/S	-	EPS this Y	41.94%	Inst Trans	-	Short Ratio	0.28	Perf Half Y	15.63%
Book/sh	0.39	P/B	1.25	EPS next Y	-27.78%	ROA	-84.07%	Short Interest	0.07M	Perf Year	-66.17%
Cash/sh	0.41	P/C	1.18	EPS next 5Y	-	ROE	-94.50%	52W Range	0.36 - 3.14	Perf YTD	-34.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-78.27%	52W High	-84.54%	Beta	1.76
Dividend TTM	-	Quick Ratio	8.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	34.83%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	8.01	EPS Y/Y TTM	-15.91%	Oper. Margin	0.00%	RSI (14)	49.51	Volatility	7.99% 8.32%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	76.46%	Payout	-	Rel Volume	0.26	Prev Close	0.49
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	247.09K	Price	0.49
SMA20	10.51%	SMA50	-10.18%	SMA200	-28.51%	Trades		Volume	68,525	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-23	Initiated	Noble Capital Markets	Outperform	$4

May-09-24 01:53PM	CVKD Stock Earnings: Cadrenal Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update (PR Newswire)
Apr-11-24 04:30PM	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 (PR Newswire)
Apr-09-24 09:00AM	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts (PR Newswire) -19.86%
Mar-11-24 09:00AM	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update (PR Newswire)
09:00AM	Loading…
Feb-26-24 09:00AM	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference (PR Newswire)
Feb-08-24 09:00AM	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial (PR Newswire) -19.47%
Jan-31-24 09:00AM	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions (PR Newswire) +8.33%
Jan-24-24 09:00AM	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (PR Newswire) +19.25%
Jan-04-24 09:00AM	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference (PR Newswire)
Dec-19-23 09:00AM	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target (PR Newswire) +6.94%
Dec-12-23 09:00AM	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization (PR Newswire)
Nov-30-23 04:15PM	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 (PR Newswire)
Nov-09-23 09:00AM	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update (PR Newswire) -5.38%
Oct-16-23 08:38AM	Innovation Takes Center Stage: Florida's Life Sciences Leaders Shine at BioFlorida Conference (PR Newswire)
04:15PM	Loading…
Oct-09-23 04:15PM	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Sep-05-23 08:00AM	Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress (PR Newswire)
Aug-30-23 08:00AM	Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS) (PR Newswire)
Aug-28-23 04:15PM	Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 09:00AM	Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update (PR Newswire)
Aug-01-23 09:00AM	Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases (PR Newswire)
Jul-24-23 09:00AM	Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors (PR Newswire) -11.65%
Jul-14-23 03:02PM	Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) -18.37%
Jul-12-23 03:17PM	Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules (PR Newswire) +29.31%
Jun-28-23 06:23AM	The 3 Hottest IPOs to Buy Before They Soar (InvestorPlace)
Jun-01-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston (PR Newswire)
May-10-23 09:00AM	Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update (PR Newswire)
May-09-23 04:30PM	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
Mar-30-23 09:00AM	Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update (PR Newswire) +8.53%
Mar-09-23 09:00AM	Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population (PR Newswire) -7.69%
09:00AM	Loading…
Feb-08-23 09:00AM	Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023 (PR Newswire) -9.26%
Feb-06-23 09:00AM	Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference (PR Newswire) -6.25%
Feb-01-23 09:00AM	Cadrenal Therapeutics Announces Formation of Scientific Advisory Board (PR Newswire)
Jan-24-23 02:11PM	Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering (PR Newswire) -18.37%
Jan-23-23 11:39AM	What's Going On With Cadrenal Therapeutics Stock Today (Benzinga)
08:30AM	Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation (PR Newswire)
Jan-20-23 09:31AM	Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) (PR Newswire)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MURPHY JOHN RAYMOND	Director	Oct 05 '23	Buy	0.69	2,669	1,842	614,792	Oct 06 05:32 PM
MURPHY JOHN RAYMOND	Director	Oct 04 '23	Buy	0.70	17,331	12,132	612,123	Oct 06 05:32 PM
Pham Quang X	CEO and Chairman	Sep 05 '23	Buy	0.90	40,000	36,188	3,410,000	Sep 06 03:28 PM
Pham Quang X	CEO and Chairman	Sep 01 '23	Buy	0.91	70,000	63,945	3,370,000	Sep 05 06:05 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVKD

Cadrenal Therapeutics Inc

Upgrade your FINVIZ experience